{"id":52487,"date":"2023-01-03T18:02:29","date_gmt":"2023-01-03T17:02:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/"},"modified":"2023-01-03T18:02:29","modified_gmt":"2023-01-03T17:02:29","slug":"ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/","title":{"rendered":"OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023"},"content":{"rendered":"<div>\n<p>NANTES, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230103005299\/en\/545518\/5\/OSE_LOGO_Horizontal_RVB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230103005299\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg\"><\/a><\/p>\n<p>\n<b>OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)<\/b> (Paris:OSE) today announces that its management team will participate in the upcoming investor events in the first quarter of 2023:\n<\/p>\n<p>\n&#8211; <b>J.P. Morgan Healthcare Conference<\/b> &#8211; San Francisco, CA, US<br \/>\n<br \/>January 9-12\n<\/p>\n<p>\n&#8211; <b>Invest Securities BioMed Event<\/b> &#8211; Paris, France<br \/>\n<br \/>January 24\n<\/p>\n<p>\n&#8211; <b>Degroof Petercam Healthcare Conference<\/b> &#8211; Brussels, Belgium<br \/>\n<br \/>January 26\n<\/p>\n<p>\n<b>ABOUT OSE Immunotherapeutics<br \/>\n<br \/><\/b>OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation.<br \/>\n<br \/>The Company\u2019s current well-balanced first-in-class clinical pipeline includes:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Tedopi\u00ae<\/b> (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company\u2019s most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi\u00ae in combination are ongoing in solid tumors.\n<\/li>\n<li>\n<b>OSE-279 <\/b>(anti-PD1): ongoing Phase 1\/2 in solid tumors or lymphomas (first patient included). OSE-279 is the backbone therapy of the BiCKI\u00ae platform.\n<\/li>\n<li>\n<b>OSE-127<\/b>\/<b>S95011<\/b> <i>lusvertikimab<\/i> (humanized monoclonal antibody antagonist of IL-7 receptor) developed in partnership with Servier; ongoing Phase 2 in ulcerative colitis (sponsor OSE Immunotherapeutics) and ongoing Phase 2a in Sj\u00f6gren\u2019s syndrome (sponsor Servier); ongoing pre-clinical research in leukemia (OSE Immunotherapeutics).\n<\/li>\n<li>\n<b>FR-104\/VEL-101 <\/b>(anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1\/2 in renal transplant (sponsor Nantes University Hospital); Phase 1 ongoing in the US (sponsor Veloxis Pharmaceuticals, Inc.).\n<\/li>\n<li>\n<b>OSE-172\/BI 765063<\/b> (anti-SIRP\u03b1 monoclonal antibody on CD47\/SIRP\u03b1 pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results in monotherapy and in combination, in particular with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing clinical trial in combination with ezabenlimab alone or with other drugs in patients with recurrent\/metastatic head and neck squamous cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC).\n<\/li>\n<\/ul>\n<p>\nOSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>BiCKI\u00ae platform<\/b> focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced BiCKI\u00ae candidate targeting anti-PD1xIL-7.\n<\/li>\n<li>\n<b>Myeloid platform<\/b> focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&amp;I). <b>OSE-230 <\/b>(ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.\n<\/li>\n<\/ul>\n<p>\nAdditional information about OSE Immunotherapeutics assets is available on the Company\u2019s website: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ose-immuno.com&amp;esheet=53155913&amp;newsitemid=20230103005299&amp;lan=en-US&amp;anchor=www.ose-immuno.com&amp;index=1&amp;md5=f47e1e2919be92428b5f55840ee0360b\" rel=\"nofollow noopener\" shape=\"rect\">www.ose-immuno.com<\/a>\n<\/p>\n<p>\nClick and follow us on\u00a0<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FOSEIMMUNO&amp;esheet=53155913&amp;newsitemid=20230103005299&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=e24f7ddc8c39525da88bc0da7b8a47ee\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>\u00a0and\u00a0<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2F10929673&amp;esheet=53155913&amp;newsitemid=20230103005299&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=e0a6b19050fdd0db136d248002bb3d46\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>\n<\/p>\n<p>\n<b>Forward-looking statements<br \/>\n<br \/><\/b>This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics\u2019 management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.<br \/>\n<br \/>These forward-looking statements include statements typically using conditional and containing verbs such as \u201cexpect\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201ctarget\u201d, \u201cplan\u201d, or \u201cestimate\u201d, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics\u2019 shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2022, including the annual financial report for the fiscal year 2021, available on the OSE Immunotherapeutics\u2019 website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>OSE Immunotherapeutics<\/b><br \/>Sylvie D\u00e9try<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#111;&#x3a;&#x73;&#x79;&#x6c;&#x76;ie&#46;&#100;&#101;&#116;&#x72;&#x79;&#x40;&#x6f;&#x73;e-&#105;&#109;&#109;&#117;&#x6e;&#x6f;&#x2e;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x73;y&#x6c;&#118;&#x69;&#101;&#x2e;&#x64;e&#x74;&#114;&#x79;&#64;&#x6f;&#115;e&#x2d;&#105;&#x6d;&#109;&#x75;&#110;o&#x2e;&#99;&#x6f;&#109;<\/a><br \/>+33 1 53 198 757\n<\/p>\n<p>\n<b>Investor Relations<\/b><br \/>Thomas Guillot<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x74;&#x68;&#x6f;&#x6d;&#x61;&#x73;&#x2e;&#x67;&#x75;&#x69;&#x6c;&#x6c;&#x6f;&#x74;&#x40;&#x6f;&#x73;&#x65;&#x2d;&#x69;&#x6d;&#x6d;&#x75;&#x6e;&#x6f;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#116;&#x68;&#x6f;&#109;&#x61;&#x73;&#46;&#x67;&#x75;&#105;&#x6c;&#x6c;&#111;&#x74;&#x40;&#111;&#x73;&#x65;&#45;&#x69;&#x6d;&#109;&#x75;&#x6e;&#111;&#x2e;&#x63;o&#x6d;<\/a><br \/>+33 6 07 380 431\n<\/p>\n<p>\n<b>French Media: FP2COM<\/b><br \/>Florence Portejoie<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;l&#x74;&#x6f;&#58;fp&#x6f;&#x72;&#116;e&#x6a;&#x6f;&#105;&#101;&#64;&#x66;&#x70;&#50;c&#x6f;&#x6d;&#46;&#102;r\" rel=\"nofollow noopener\" shape=\"rect\">&#102;&#x70;&#111;&#x72;t&#101;&#x6a;&#111;&#x69;e&#x40;f&#112;&#x32;&#99;&#x6f;m&#x2e;&#x66;&#114;<\/a><br \/>+33 6 07 768 283\n<\/p>\n<p>\n<b>International Media<\/b>: <b>MEDiSTRAVA Consulting<\/b><br \/>Sylvie Berrebi \/ David Dible \/ Eleanor Perkin<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#111;&#x3a;&#79;&#x53;E&#x49;m&#109;&#x75;&#110;&#x6f;&#64;&#x6d;&#x65;&#100;&#x69;s&#x74;r&#97;&#x76;&#97;&#x2e;c&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#79;&#x53;&#69;&#x49;&#109;&#x6d;&#117;&#x6e;&#111;&#x40;&#109;&#x65;&#100;&#x69;&#115;&#x74;&#114;&#x61;&#118;&#x61;&#46;&#x63;&#111;&#x6d;<\/a><br \/>+44 203 928 6900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>NANTES, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announces that its management team will participate in the upcoming investor events in the first quarter of 2023: &#8211; J.P. Morgan Healthcare Conference &#8211; San Francisco, CA, US January 9-12 &#8211; Invest Securities BioMed Event &#8211; Paris, France January 24 &#8211; Degroof &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52487","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NANTES, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announces that its management team will participate in the upcoming investor events in the first quarter of 2023: &#8211; J.P. Morgan Healthcare Conference &#8211; San Francisco, CA, US January 9-12 &#8211; Invest Securities BioMed Event &#8211; Paris, France January 24 &#8211; Degroof ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-03T17:02:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230103005299\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023\",\"datePublished\":\"2023-01-03T17:02:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/\"},\"wordCount\":773,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005299\\\/en\\\/545518\\\/21\\\/OSE_LOGO_Horizontal_RVB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/\",\"name\":\"OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005299\\\/en\\\/545518\\\/21\\\/OSE_LOGO_Horizontal_RVB.jpg\",\"datePublished\":\"2023-01-03T17:02:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005299\\\/en\\\/545518\\\/21\\\/OSE_LOGO_Horizontal_RVB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005299\\\/en\\\/545518\\\/21\\\/OSE_LOGO_Horizontal_RVB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/","og_locale":"en_US","og_type":"article","og_title":"OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023 - Pharma Trend","og_description":"NANTES, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announces that its management team will participate in the upcoming investor events in the first quarter of 2023: &#8211; J.P. Morgan Healthcare Conference &#8211; San Francisco, CA, US January 9-12 &#8211; Invest Securities BioMed Event &#8211; Paris, France January 24 &#8211; Degroof ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-03T17:02:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230103005299\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023","datePublished":"2023-01-03T17:02:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/"},"wordCount":773,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230103005299\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/","url":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/","name":"OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230103005299\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg","datePublished":"2023-01-03T17:02:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230103005299\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230103005299\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-upcoming-investor-meetings-in-q1-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52487"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52487\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}